Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

Phase 1

Active, not recruiting

• Conditions: Tumors Metastatic to Brain; Unspecified Adult Solid Tumor
• Interventions: Radiation: stereotactic radiosurgery; Procedure: quality-of-life assessment; Procedure: cognitive assessment

• Registration Number: NCT01843413
• Lead Sponsor: Case Comprehensive Cancer Center

Brief Summary

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the incidence of acute and long-term toxicities with increasing dose of stereotactic radiosurgery (SRS). (Phase I) II. To determine if local control may be improved with increasing doses of SRS. (Phase II)

SECONDARY OBJECTIVES:

I. To determine the risk of acute and long-term toxicity with increasing dose of SRS. (Phase II) II. To determine if there is increased neurocognitive toxicity with increased dose of SRS.

III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine if quality of life is affected more by tumor recurrence versus radiation necrosis. This includes assessment of progression free survival, overall survival, local failure, and number of patients who receive bevacizumab, laser interstitial thermal therapy, or surgery for presumed radiation necrosis.

OUTLINE: This is a phase I dose-escalation study followed by a phase II study.

Patients undergo SRS guided by computer tomography (CT) and magnetic resonance imaging (MRI).

After completion of treatment, patients are followed up at 1-2, 3, 6, 9, and 12 months, every 3 months for 2 years, and then every 4 months thereafter.

Study Timeline

• Study First Submitted: 2013-04-26
• Study First Submitted QC: 2013-04-29
• Study First Posted: 2013-04-30
• Study Start: 2013-07-02
• Status Verified: 2025-04
• Primary Completion: 2025-04
• Study Completion: 2025-04
• Last Update Submitted: 2025-04-01
• Last Update Posted: 2025-04-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Any patient undergoing SRS for brain metastases

• Lesions to be treated under this protocol must be > 2 cm, but =< 4.0 cm in diameter

• Patients may have had prior therapy including:

  • Whole brain radiation therapy (WBRT) > 3 months ago
  • SRS to other brain metastases

• Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront

• Any primary is eligible with exception of small cell lung cancer, lymphoma, and germ cell histologies

• Patient must be able to provide written informed consent

Exclusion Criteria

• Patients receiving SRS to resection bed
• Planned concurrent WBRT
• Leptomeningeal metastases
• Small cell lung cancer, lymphoma, and germ cell histologies
• Inability to participate in study activities due to physical or mental limitations
• Inability or unwillingness to return for all the required follow-up visits
• Conformality index 2.0 or less cannot be achieved, or homogeneity index is > 2.0
• Unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm
• Brainstem location is excluded from this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (SRS)	quality-of-life assessment	Patients undergo SRS guided by CT and MRI.
Treatment (SRS)	cognitive assessment	Patients undergo SRS guided by CT and MRI.
Treatment (SRS)	stereotactic radiosurgery	Patients undergo SRS guided by CT and MRI.

Primary Outcome Measures

Name	Time	Method
Maximum-tolerated dose based on the incidence of dose-limiting toxicity (DLT) defined as any grade III or IV toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)	Up to 4 months
Response associated with increased dose of SRS as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)	Up to 2 years

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse events as assessed by CTCAE version 4.0 (Phase II)	Up to 2 years	Toxicity will be summarized as frequencies and percentages with a corresponding exact 95% confidence interval.
Quality of life (QOL) as assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and the European Organization for Research and Treatment (EORTC)- Quality of Life Questionnaire Core 30 (QLQ30)	Up to 12 months

Trial Locations

Locations (1)

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center; 🇺🇸 Cleveland, Ohio, United States